Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

As physicians across specialties encounter increasing patient interest in GLP-1 receptor agonists, it is important for them ...

Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...

Biotech innovator accelerated growth in 2025, doubled headcount, and expanded operations in the US The Cradle platform provides AI protein design tools trained on unique customer data and tailored for ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...